Outcomes in COVID-19 adintrevimab studies
Outcomes in adintrevimab studies. mAb use may create new variants that spread globally
Focosi , Leducq , and may be associated with prolonged viral loads, clinical deterioration, and immune escape
Choudhary , Günther , Leducq .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 studies
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Effect extraction pre-specified
(most serious outcome)
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
0/240
1/241
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 mortality results
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
84%
0.16 [0.02-1.34]
hosp.
1/752
6/728
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
80%
0.20 [0.01-4.15]
hosp.
0/175
2/176
Tau
2
= 0.00, I
2
= 0.0%, p = 0.047
Prophylaxis
83%
0.17 [0.03-0.98]
1/927
8/904
83% lower risk
All studies
83%
0.17 [0.03-0.98]
1/927
8/904
83% lower risk
2 adintrevimab COVID-19 hospitalization results
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.047
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 serious outcomes
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Effect extraction pre-specified
(most serious outcome)
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
70%
0.30 [0.16-0.56]
symp. case
12/752
39/728
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
75%
0.25 [0.07-0.88]
symp. case
3/175
12/176
Tau
2
= 0.00, I
2
= 0.0%, p < 0.0001
Prophylaxis
71%
0.29 [0.16-0.51]
15/927
51/904
71% lower risk
All studies
71%
0.29 [0.16-0.51]
15/927
51/904
71% lower risk
2 adintrevimab COVID-19 case results
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p < 0.0001
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 Randomized Controlled Trials
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Effect extraction pre-specified
(most serious outcome)
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
0/240
1/241
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 RCT mortality results
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Prophylaxis
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
All studies
43%
0.57 [0.12-2.69]
2/1,241
4/1,242
43% lower risk
2 adintrevimab COVID-19 peer reviewed studies
c19
early
.org
April 2024
Tau
2
= 0.00, I
2
= 0.0%, p = 0.48
Effect extraction pre-specified
(most serious outcome)
Favors adintrevimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
EVADE PrEP
Ison (DB RCT)
33%
0.67 [0.11-3.98]
death
2/1,001
3/1,001
Improvement, RR [CI]
Treatment
Control
EVADE PrEP
Ison (DB RCT)
50%
0.50 [0.13-1.99]
death
3/1,001
6/1,001
EVADE PrEP
Ison (DB RCT)
84%
0.16 [0.02-1.34]
death
1/752
6/728
EVADE PrEP
Ison (DB RCT)
84%
0.16 [0.02-1.34]
hosp.
1/752
6/728
EVADE PrEP
Ison (DB RCT)
70%
0.30 [0.16-0.56]
symp. case
12/752
39/728
EVADE PEP
Ison (DB RCT)
67%
0.33 [0.01-8.15]
death
0/240
1/241
EVADE PEP
Ison (DB RCT)
80%
0.20 [0.01-4.15]
death
0/240
2/241
EVADE PEP
Ison (DB RCT)
80%
0.20 [0.01-4.15]
hosp.
0/175
2/176
EVADE PEP
Ison (DB RCT)
75%
0.25 [0.07-0.88]
symp. case
3/175
12/176
Adintrevimab COVID-19 outcomes
c19
early
.org
April 2024
Favors adintrevimab
Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers.
Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.
FLCCC and
WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit